Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride, quantity: 150 mg/ml - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections - indications as at 04 november 2004 : 1.the treatment hypokalaemia. 2. treatment of digitalis intoxication. the iv route is indicated when the patient is unable to take potassium orally or if hypokalaemia is severe.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride, quantity: 200 mg/ml - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections - indications as at 04 november 2004 : 1.the treatment hypokalaemia. 2. treatment of digitalis intoxication. the iv route is indicated when the patient is unable to take potassium orally or if hypokalaemia is severe.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections - indications as at 04 november 2004 : 1.the treatment hypokalaemia.2. treatment of digitalis intoxication. the iv route is indicated when the patient is unable to take potassium orally or if hypokalaemia is severe.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride, quantity: 75 mg/ml - injection, concentrated - excipient ingredients: water for injections - indications as at 04 november 2004 : 1.the treatment hypokalaemia. 2. treatment of digitalis intoxication. the iv route is indicated when the patient is unable to take potassium orally or if hypokalaemia is severe.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - propranolol hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; calcium carbonate; pregelatinised maize starch; gelatin; titanium dioxide; hypromellose; sunset yellow fcf; erythrosine; macrogol 400 - 1. angina pectoris. 2. hypertension. 3. prevention of migraine. 4. cardiac dysrythmias: certain intrinsic cardiac dysrythmias; dysrythmias associated with thyrotoxicosis; anxiety tachycardia; certain drug induced dysrythmias (eg. tachycardia due to digitalis or adrenaline overdosage). 5. essential tremor including familial and senile tremor. 6. phaeochromocytoma (only with concurrent alpha antagonist). 7. hypertrophic subaortic stenosis. 8. suspected or definite myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - propranolol hydrochloride, quantity: 160 mg - tablet, film coated - excipient ingredients: magnesium stearate; calcium carbonate; croscarmellose sodium; gelatin; pregelatinised maize starch; titanium dioxide; hypromellose; sunset yellow fcf; erythrosine; macrogol 400 - 1. angina pectoris. 2. hypertension. 3. prevention of migraine. 4. cardiac dysrythmias: certain intrinsic cardiac dysrythmias; dysrythmias associated with thyrotoxicosis; anxiety tachycardia; certain drug induced dysrythmias (eg. tachycardia due to digitalis or adrenaline overdosage). 5. essential tremor including familial and senile tremor. 6. phaeochromocytoma (only with concurrent alpha antagonist). 7. hypertrophic subaortic stenosis. 8. suspected or definite myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - propranolol hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; croscarmellose sodium; calcium carbonate; magnesium stearate; gelatin; titanium dioxide; hypromellose; sunset yellow fcf; erythrosine; macrogol 400 - 1. angina pectoris. 2. hypertension. 3. prevention of migraine. 4. cardiac dysrythmias: certain intrinsic cardiac dysrythmias; dysrythmias associated with thyrotoxicosis; anxiety tachycardia; certain drug induced dysrythmias (eg. tachycardia due to digitalis or adrenaline overdosage). 5. essential tremor including familial and senile tremor. 6. phaeochromocytoma (only with concurrent alpha antagonist). 7. hypertrophic subaortic stenosis. 8. suspected or definite myocardial infarction.

United States - English - NLM (National Library of Medicine)

guna spa - ferric picrate (unii: kzm8zry36a) (ferric cation - unii:91o4lml611), chaste tree (unii: 433osf3u8a) (chaste tree - unii:433osf3u8a), barium carbonate (unii: 6p669d8hq8) (barium cation - unii:v645272hln), chimaphila umbellata (unii: wck21a9w9j) (chimaphila umbellata - unii:wck21a9w9j), clematis recta flowering top (unii: 396421sp9f) (clematis recta flowering top - unii:396421sp9f), conium maculatum flowering top (unii: q28r5gf371) (conium maculatum flowering top - unii:q28r5gf371), digitalis (unii: f1t - chaste tree 6 [hp_x] in 30 ml - agnus castus        6x    incontinence baryta carbonica    12x 30x    painful urination chimaphila umbellata    6x    detoxification clematis erecta        3x    antioxidant conium maculatum    12x 30x    antioxidant digitalis purpurea    12x 30x    relieves urinary irritation ferrum picrinicum    12x 30x    sudden urge to urinate interferon gamma    4c    antioxidant interleukin 10        4c    painful urination interleukin 2        4c    painful urination melatonin        4c    hormonal regulation prostate        200x    painful urination sabal serrulata        3x    painful urination selenium metallicum    12x 30x    slowed start of urination staphysagria        12x 30x    painful urination tgf beta        4c    painful urination thuja occidentalis    12x 30x    slowed start of urinatio

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pindolol, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; colloidal anhydrous silica - indications as at 18 november 2004: hypertension (either alone or in combination with other antihypertensive drugs). angina pectoris (prevention of attacks). cardiac arrhythmias [sinus tachycardia, paroxysmal tachycardia, supraventricular and ventricular extrasystoles, drug induced extrasystoles (digitalis), atrial flutter and fibrillation - to slow the ventricular rate]. functional hyperadrenergic cardiac disturbances (hyperkinetic heart syndrome, neurocirculatory asthenia).

Israel - English - Ministry of Health

organon pharma israel ltd., israel - losartan potassium - tablets - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar 50 mg is indicated for the treatment of hypertensionheart failure: ocsaar 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to ocsaar 50 mg is not recommended.renal protection in type-2 diabetic patients with proteinuria: ocsaar 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.the benefit of ocsaar 50 mg on the primary deposite endpoint was largely driven by reduction in the risk of stroke.